Your PSA Came Back High: What the Number Means and What Happens Next

Why is PSA a prostate marker and not a prostate cancer test?

PSA is produced by prostate tissue. Elevated PSA is non-specific: it rises with benign prostate conditions, inflammation, and certain activities — not only cancer 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups2Ref 2US Preventive Services Task Force (2018).Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.Shared decision-making emphasis; trade-offs between benefits and harms of PSA follow-up including biopsy risks and over-treatment. A high result means your prostate is producing more PSA than expected for your age and size, but it does not mean cancer is present.

Most guidelines do not use a single universal cutoff for "normal" PSA because interpretation depends on your age, prostate size, the trend over time, and your individual risk factors 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups. Importantly, many men with prostate cancer have a PSA in the "normal" range, and many men with elevated PSA do not have cancer. PSA is a screening signal — a reason to look further — not a definitive answer.

What commonly raises PSA besides cancer?

The most frequent causes of an elevated PSA, in rough order of how commonly they arise:

Benign prostatic hyperplasia (BPH) — the most common reason for a moderately elevated PSA in men over 50. The prostate growing with age naturally produces more PSA 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups.

Prostatitis — inflammation or infection of the prostate can spike PSA considerably, sometimes in men who feel entirely well. Bacterial prostatitis and non-bacterial inflammation both raise it.

Recent ejaculation — PSA can rise transiently after ejaculation. Many labs recommend abstaining for 48 hours before testing, though not all providers give this instruction.

Recent prostate exam or procedure — digital rectal exam, catheter insertion, or cystoscopy can temporarily elevate PSA.

Vigorous cycling — sustained perineal pressure from long bike rides is a documented, modest contributor.

Medications that suppress PSA — finasteride and dutasteride (used for BPH or hair loss) can cut PSA values roughly in half 3Ref 3Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G (2010).Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review.Finasteride's suppression of PSA levels, requiring correction when interpreting PSA results in men taking the medication. An apparently "normal" PSA in a man taking these medications may actually be elevated relative to the true baseline — disclosing these medications to your clinician is essential.

What will my clinician likely do after a high PSA?

The approach varies based on the number, your age, prior results, and overall health. Common next steps 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups2Ref 2US Preventive Services Task Force (2018).Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.Shared decision-making emphasis; trade-offs between benefits and harms of PSA follow-up including biopsy risks and over-treatment:

Repeat the PSA — a single elevated value may reflect a transient cause. Many clinicians will repeat it a few weeks later under controlled conditions (no ejaculation 48 hours prior, no recent prostate exam, no active infection) before deciding on further steps.

Digital rectal exam (DRE) — a brief physical exam to feel the prostate for nodules or irregularities. A normal-feeling prostate lowers — but does not eliminate — concern.

PSA refinements — free-to-total PSA ratio, PSA density (adjusted for prostate size), and PSA velocity (how much it has risen over time) help distinguish benign from concerning elevations.

Urology referral — if the number is significantly elevated, rising, or combined with concerning exam findings, your primary-care clinician may refer you to a urologist for further evaluation.

Prostate MRI — increasingly used before or instead of biopsy to characterize suspicious areas and reduce unnecessary biopsies.

Prostate biopsy — the only definitive way to detect or exclude prostate cancer; recommended based on risk assessment, not automatically for any single elevated PSA.

Why is shared decision-making central to this conversation?

PSA follow-up involves real trade-offs 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups2Ref 2US Preventive Services Task Force (2018).Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.Shared decision-making emphasis; trade-offs between benefits and harms of PSA follow-up including biopsy risks and over-treatment. Biopsies carry small risks of infection and discomfort. Prostate cancer found through screening is sometimes slow-growing and may never cause symptoms in a man's lifetime, while other prostate cancers are aggressive and need treatment.

Major guidelines emphasize that men should make decisions about PSA follow-up in an informed conversation with their clinician — weighing age, life expectancy, family history, and personal values around risk and intervention 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups2Ref 2US Preventive Services Task Force (2018).Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.Shared decision-making emphasis; trade-offs between benefits and harms of PSA follow-up including biopsy risks and over-treatment. If your clinician presents you with a genuine choice about next steps, that is not evasion — it reflects the fact that reasonable men may choose differently based on their priorities.

This is a good moment to ask questions and make sure you understand what each option involves before agreeing to any next step.